Reference : Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporo...
Scientific journals : Article
Human health sciences : Rheumatology
Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
Kung, Annie Wai-Chee [> >]
Rachman, A Ichramsjah [> >]
Adam, MF John [> >]
Roeshadi, Djoko [> >]
Torralba, Tito [> >]
Navarra, Sandra [> >]
Gamilla, Zayda [> >]
Cañete, Arthur [> >]
de la Rosa, Miles [> >]
Tsai, KehSung [> >]
Lin, Hsiao-Yi [> >]
Soong, Yung Kuei [> >]
Lan, Joung-Liang [> >]
Hsu, Horng-Chaung [> >]
Tu, Shih-Te [> >]
Lin, Ruey-Mo [> >]
Yuktanandana, Pongsak [> >]
Songpatanasilp, Thawee [> >]
Ngarmukos, Srihatach [> >]
Soontrapa, Sugree [> >]
Soontrapa, Suppasin [> >]
Rojanasthien, Sattaya [> >]
Luevitoonvechkij, Sirichai [> >]
Leerapan, Taninnit [> >]
Albert, Adelin mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique - Département de mathématique >]
Vanbelle, Sophie mailto [Université de Liège - ULiège > Département de mathématique > Département de mathématique >]
International Journal of Rheumatic Diseases
Yes (verified by ORBi)
[en] adherence ; bone marker ; compliance ; feedback ; ibandronate ; osteoporosis
[en] Aim: This study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker
feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis.
Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study
conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (£ 85 years old) who were
naı¨ve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at
3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and
adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate
treatment were also assessed.
Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients
were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels
were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their
osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients.
Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to
once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence,
but increased treatment satisfaction.
the BonAdAsia study group

File(s) associated to this reference

Fulltext file(s):

Restricted access
bonadasia.pdfPublisher postprint180.33 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.